Inappropriately and persistently activated STAT3 have been estimated to occur in approximately 70% of hematopoietic and solid malignancies, including melanoma (Johnston and Grandis, 2011; Laudisi et al., 2018). This evidence concerns the gene STAT3 and cancer.